Glucose Transporters

Glucose is a hydrophilic molecule that cannot pass through the cell membrane's hydrophobic lipid bilayer. Instead, it requires specific membrane transport proteins called glucose transporters to cross the membrane. These transporters enable glucose movement through facilitated diffusion or secondary active transport mechanisms.

GLUTs are uniporters that facilitate diffusion of glucose down its concentration gradient without energy input. SGLTs are symporters that use the sodium gradient to transport glucose against its concentration gradient through secondary active transport. SGLT1, found in the small intestine, simultaneously transports two sodium ions and one glucose molecule.

GLUT4 is found in cardiac and skeletal muscles and is called the insulin-responsive glucose transporter. It transports glucose into muscle cells in response to insulin hormone signaling. This insulin-dependent mechanism allows muscles to take up glucose when blood glucose levels are elevated after meals.

The human body has 14 different GLUT protein types, named GLUT1 through GLUT14, organized into three classes based on sequence homology. Additionally, six SGLT protein isoforms exist. These transporters are distributed across various organs and tissues to maintain glucose homeostasis throughout the body.

GLUT1 is ubiquitously expressed in all tissues but is predominantly found in erythrocytes and endothelial cells of the blood-brain barrier. It facilitates glucose transport across the blood-brain barrier, ensuring the brain receives adequate glucose supply. GLUT3 is also mainly present in brain tissue to support neuronal glucose uptake.

Defects in the SGLT1 gene cause intestinal glucose-galactose malabsorption, an autosomal recessive disorder. This condition results in severe osmotic diarrhea and dehydration shortly after birth because glucose cannot be properly absorbed into the small intestine. The inability to transport glucose and galactose prevents normal nutrient absorption.

GLUT1 deficiency syndrome, caused by mutations in the SLC2A1 gene, impairs glucose transport at the blood-brain barrier. Clinical symptoms include early-onset epileptic encephalopathy, microcephaly, and seizures. This condition is thought to be inherited in an autosomal dominant manner and affects the brain's glucose supply.